- Home
- DSU vs KROS Comparison
DSU vs KROS Comparison
Compare DSU & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSU
- KROS
- Stock Information
- Founded
- DSU 1998
- KROS 2015
- Country
- DSU United States
- KROS United States
- Employees
- DSU N/A
- KROS N/A
- Industry
- DSU Finance Companies
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- DSU Finance
- KROS Health Care
- Exchange
- DSU Nasdaq
- KROS Nasdaq
- Market Cap
- DSU 548.1M
- KROS 565.0M
- IPO Year
- DSU N/A
- KROS 2020
- Fundamental
- Price
- DSU $10.52
- KROS $14.48
- Analyst Decision
- DSU
- KROS Buy
- Analyst Count
- DSU 0
- KROS 14
- Target Price
- DSU N/A
- KROS $20.56
- AVG Volume (30 Days)
- DSU 148.2K
- KROS 426.9K
- Earning Date
- DSU 01-01-0001
- KROS 08-06-2025
- Dividend Yield
- DSU 10.06%
- KROS N/A
- EPS Growth
- DSU N/A
- KROS N/A
- EPS
- DSU N/A
- KROS 0.47
- Revenue
- DSU N/A
- KROS $232,844,000.00
- Revenue This Year
- DSU N/A
- KROS $5,390.70
- Revenue Next Year
- DSU N/A
- KROS N/A
- P/E Ratio
- DSU N/A
- KROS $30.99
- Revenue Growth
- DSU N/A
- KROS 85820.30
- 52 Week Low
- DSU $9.22
- KROS $9.12
- 52 Week High
- DSU $11.40
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- DSU 45.35
- KROS 55.85
- Support Level
- DSU $10.51
- KROS $13.78
- Resistance Level
- DSU $10.59
- KROS $14.67
- Average True Range (ATR)
- DSU 0.05
- KROS 0.45
- MACD
- DSU -0.01
- KROS 0.00
- Stochastic Oscillator
- DSU 16.67
- KROS 80.38
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.